Table 2. Absolute and relative sensitivity and specificity of hrHPV testing vs cytology, adjusted for non-attendance at repeat testing.
| Screening test a | End point CIN3+ | End point CIN2+ |
|---|---|---|
| (95% CI) | (95% CI) | |
| Sensitivity | ||
| hrHPV | 91.9% (61.0–96.7) | 82.0% (62.9–89.6) |
| Cytology | 64.6% (43.3–73.1) | 50.5% (38.4–58.0) |
| Specificity | ||
| hrHPV | 95.6% (95.3–95.8) | 96.0% (95.7–96.3) |
| Cytology | 98.7% (98.5–98.8) | 98.9% (98.7–99.0) |
| Relative sensitivity | ||
| hrHPV vs cytology | 1.42 (1.19–1.67) | 1.63 (1.40–1.89) |
| Relative specificity | ||
| hrHPV vs cytology | 0.969 (0.966–0.971) | 0.971 (0.968–0.974) |
Abbreviations: hrHPV=high-risk human papillomavirus; CI=confidence interval; CIN=cervical intraepithelial neoplasia (grade 2 or 3 or higher).
a
Cytology positivity was defined as a result of borderline or mild dyskaryosis or worse (⩾BMD).